Company news
Imugene Ltd (ASX:IMU) news
Imugene Ltd news releases on 6ix. Latest, Oct 4, 2026: azer-cel BTKi Cohort Reports new Complete & Partial Response
Press releases & updates
azer-cel BTKi Cohort Reports new Complete & Partial Response
October 4, 2026
Third response in concurrent BTKi Cohort of azer-cel Trial
July 26, 2026
$11.1 Million Placement Completed to Advance azer-cel
July 6, 2026
New Complete Response in the Concurrent BTKi azer-cel Cohort
June 30, 2026
First Complete Response in Concurrent BTKi azer-cel Cohort
June 29, 2026
Azer-cel Granted FDA Fast Track Designation for CLL and MZL
June 8, 2026
First Patient in BTKi Combination Cohort of azer-cel study
May 27, 2026
Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
May 21, 2026
Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
May 20, 2026
Prospectus
March 17, 2026
$20M placement and SPP, convertible notes amended
March 11, 2026
100% and 80% ORRs in Subset Indications in azer-cel study
March 9, 2026
Trading Halt
March 9, 2026
Half Yearly Report and Accounts
February 25, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
FDA Supports Strategy Toward Registration for Azer-cel
December 7, 2025
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
November 27, 2025
Strategic Collaboration with JW Therapeutics
November 26, 2025
S&P DJI Announces September 2025 Quarterly Rebalance
September 5, 2025
Final Share Purchase Plan Allotment
August 28, 2025
Appendix 4E and Annual Report
August 25, 2025
Imugene Capital Raising Presentation
July 16, 2025
Imugene Completes $22.5M Placement and c.$15M SPP
July 16, 2025
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
July 14, 2025
Two Additional Complete Responses in azer-cel Ph1b trial
July 13, 2025
Notice of Extraordinary General Meeting/Proxy Form
May 27, 2025
Azer-cel Granted FDA Fast Track Designation in Blood Cancer
March 18, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025
Imugene Granted India Patent for Oncolytic Virotherapy CF33
February 26, 2025
Imugene OnCARlytics Patent Allowance in China
February 25, 2025
Azer-cel demonstrates two additional Complete Responses
February 13, 2025
Imugene Receives A$20 million for Convertible Notes Issuance
January 28, 2025
Imugene Receives $11.7m R&D Tax Refund
January 10, 2025
First Australian Patient Dosed in Phase 1b azer-cel Trial
January 2, 2025
Issuance of Convertible Notes & Warrants for up to $46m
December 23, 2024
Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
December 18, 2024
onCARlytics Trial Doses First Patient in IT Combination Arm
November 10, 2024
Imugene Opens First Australian Site for azer-cel Trial
November 7, 2024
Complete Response in MAST Study Maintained Over Two Years
November 4, 2024
Imugene Receives Orphan Drug Designation for VAXINIA
September 18, 2024
Three Complete Responses in Azer-Cel Phase 1b Trial
September 1, 2024
First patient dosed in Phase 1 bile tract cancer trial
July 9, 2024
Imugene onCARlytics Doses First Patient in IV Combination
June 23, 2024
Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
April 16, 2024
Imugene and Kincell Bio Announce Strategic Partnership
April 15, 2024
Bile Tract Cancer Study Opens after MAST High Dose Clearance
April 14, 2024
VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
April 7, 2024
Oncolytic Virotherapy CF33 Patent Granted in China
April 3, 2024
Imugene to present at 2024 Cholangiocarcinoma Conference
April 2, 2024
Phase 1 onCARlytics Trial Advances to Combination Arm
March 10, 2024